论文部分内容阅读
40名无过敏症或耐药性、无肝肾疾病、两年内未服用过抗丝虫药而血中微丝蚴(mf)≥20条/ml的波利尼西亚男性带虫者被分为4组。组1～4分别口服1剂伊维菌素50,100,150,200μg/kg。评价伊维菌素疗效的标准为:1.治后mf下降者的比例;2.治后mf转阴者的比例;3.治后mf下降数量;4.治后微丝蚴血症复发数。结果为治后40人的mf均迅速下降。治后30天mf转阴率为组1:40％,组2:100％,组3:100％和组4:90％。mf下降数为组1超过98％,组2和组3为100％,组4超过99％。治后3个月微丝蚴血症的复发率为组1:25.8％,组2:5％,组3:4％,组4:4.5％,组1的复发率明显高于其
Forty Polygonian male worms with no allergies or drug resistance, no liver and kidney disease, no antifibrionics within two years and a blood microfilariae (mf) ≥20 / ml were divided into four groups. Groups 1 to 4 were given 1 dose of ivermectin 50,100,150,200μg / kg. The criteria for evaluating the efficacy of ivermectin are: 1. The proportion of those with decreased mf after treatment; 2. The proportion of those with mf-negative after treatment; 3. The number of mf declines after treatment; 4. The number of recurrences of microfilaremia after treatment . Results for the treatment of 40 mf are rapidly declining. On the 30th day after treatment, the rate of mf negative conversion was 1: 40% in group, 2: 100% in group, 3: 100% in group, and 4: 90% in group. The decrease in mf was more than 98% for group 1, 100% for group 2 and group 3, and 99% for group 4. The recurrence rate of microfilaremia at 3 months after treatment was 1: 25.8%, 2: 5%, 3: 4% and 4: 4.5% respectively. The recurrence rate of group 1 was significantly higher than that of group 1